Maeva Y. I. Chauvin, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Anti-Mullerian Hormone | 6 | 2025 | 420 | 1.910 |
Why?
|
Peptide Hormones | 2 | 2023 | 133 | 1.000 |
Why?
|
Ovarian Neoplasms | 4 | 2023 | 4903 | 0.760 |
Why?
|
Bone Morphogenetic Protein Receptors, Type I | 1 | 2021 | 97 | 0.720 |
Why?
|
Activin Receptors, Type I | 1 | 2021 | 133 | 0.710 |
Why?
|
Receptors, Transforming Growth Factor beta | 5 | 2023 | 304 | 0.710 |
Why?
|
Ovary | 4 | 2025 | 963 | 0.590 |
Why?
|
Receptors, Peptide | 4 | 2022 | 280 | 0.510 |
Why?
|
Ovarian Follicle | 3 | 2022 | 244 | 0.260 |
Why?
|
Cell Survival | 3 | 2021 | 5749 | 0.200 |
Why?
|
Ovulation | 1 | 2022 | 181 | 0.190 |
Why?
|
Smad5 Protein | 1 | 2021 | 26 | 0.190 |
Why?
|
Smad1 Protein | 1 | 2021 | 81 | 0.180 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2021 | 3605 | 0.180 |
Why?
|
Contraceptive Agents | 1 | 2022 | 147 | 0.180 |
Why?
|
Phosphorylation | 2 | 2021 | 8310 | 0.170 |
Why?
|
Drug Repositioning | 1 | 2022 | 246 | 0.170 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2021 | 2183 | 0.160 |
Why?
|
Caspase 3 | 1 | 2021 | 730 | 0.150 |
Why?
|
Maternal-Fetal Exchange | 1 | 2020 | 453 | 0.150 |
Why?
|
Antibodies, Bispecific | 1 | 2021 | 204 | 0.150 |
Why?
|
Doxorubicin | 1 | 2025 | 2229 | 0.150 |
Why?
|
Mice, Nude | 2 | 2021 | 3618 | 0.140 |
Why?
|
Small Molecule Libraries | 1 | 2022 | 741 | 0.130 |
Why?
|
DNA Topoisomerases, Type I | 1 | 2016 | 108 | 0.130 |
Why?
|
Cell Line, Tumor | 3 | 2021 | 17089 | 0.130 |
Why?
|
DNA Damage | 1 | 2025 | 2469 | 0.120 |
Why?
|
Placenta | 2 | 2021 | 1726 | 0.120 |
Why?
|
Chromatin Assembly and Disassembly | 1 | 2016 | 632 | 0.090 |
Why?
|
Mice | 6 | 2025 | 81898 | 0.090 |
Why?
|
Mice, Transgenic | 1 | 2023 | 9546 | 0.090 |
Why?
|
Tumor Microenvironment | 1 | 2023 | 3942 | 0.090 |
Why?
|
Antibodies, Viral | 1 | 2020 | 3213 | 0.080 |
Why?
|
DNA Replication | 1 | 2016 | 1426 | 0.080 |
Why?
|
Immunoglobulin G | 1 | 2020 | 4559 | 0.080 |
Why?
|
Animals | 8 | 2025 | 168939 | 0.070 |
Why?
|
Female | 11 | 2025 | 396532 | 0.060 |
Why?
|
Cell Proliferation | 1 | 2021 | 10451 | 0.060 |
Why?
|
Granulosa Cells | 1 | 2025 | 120 | 0.060 |
Why?
|
Population Control | 1 | 2023 | 23 | 0.050 |
Why?
|
Sterilization, Reproductive | 1 | 2023 | 24 | 0.050 |
Why?
|
Animals, Wild | 1 | 2023 | 78 | 0.050 |
Why?
|
Estrous Cycle | 1 | 2022 | 65 | 0.050 |
Why?
|
Anthracenes | 1 | 2022 | 83 | 0.050 |
Why?
|
DNA | 1 | 2016 | 7210 | 0.050 |
Why?
|
Proteomics | 1 | 2016 | 3915 | 0.050 |
Why?
|
Cats | 1 | 2023 | 972 | 0.050 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2025 | 678 | 0.050 |
Why?
|
Inhibins | 1 | 2021 | 210 | 0.040 |
Why?
|
Contraception | 1 | 2023 | 360 | 0.040 |
Why?
|
Humans | 9 | 2025 | 766812 | 0.040 |
Why?
|
Pregnancy Trimester, Third | 1 | 2020 | 587 | 0.040 |
Why?
|
Pelvis | 1 | 2022 | 737 | 0.040 |
Why?
|
Signal Transduction | 1 | 2021 | 23618 | 0.040 |
Why?
|
Receptors, IgG | 1 | 2020 | 562 | 0.040 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2022 | 1331 | 0.030 |
Why?
|
Nitriles | 1 | 2022 | 981 | 0.030 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2017 | 306 | 0.030 |
Why?
|
Topoisomerase I Inhibitors | 1 | 2016 | 70 | 0.030 |
Why?
|
Immunity | 1 | 2021 | 1002 | 0.030 |
Why?
|
Animals, Newborn | 1 | 2021 | 2677 | 0.030 |
Why?
|
DNA Repair | 1 | 2025 | 2050 | 0.030 |
Why?
|
Cell Differentiation | 2 | 2025 | 11657 | 0.030 |
Why?
|
Apoptosis | 2 | 2025 | 9514 | 0.030 |
Why?
|
Rats | 2 | 2022 | 23717 | 0.030 |
Why?
|
Transcription, Genetic | 2 | 2021 | 7612 | 0.030 |
Why?
|
Thiazoles | 1 | 2022 | 1529 | 0.030 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2021 | 1353 | 0.030 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2025 | 2952 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 2017 | 13644 | 0.030 |
Why?
|
Glycosylation | 1 | 2017 | 1099 | 0.030 |
Why?
|
Protein Engineering | 1 | 2017 | 554 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2021 | 2039 | 0.030 |
Why?
|
Camptothecin | 1 | 2016 | 599 | 0.030 |
Why?
|
Adenosine Triphosphatases | 1 | 2016 | 840 | 0.020 |
Why?
|
Pyrazoles | 1 | 2022 | 2030 | 0.020 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2016 | 724 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2021 | 8108 | 0.020 |
Why?
|
HeLa Cells | 1 | 2016 | 3073 | 0.020 |
Why?
|
Pyrimidines | 1 | 2022 | 3043 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2021 | 2535 | 0.020 |
Why?
|
Pregnancy | 2 | 2021 | 30236 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2021 | 22351 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2020 | 26387 | 0.010 |
Why?
|
Transcription Factors | 1 | 2016 | 12159 | 0.010 |
Why?
|
Adult | 1 | 2020 | 223305 | 0.000 |
Why?
|
Male | 1 | 2016 | 364154 | 0.000 |
Why?
|